Updated overall survival data from KEYNOTE-564 showed adjuvant pembrolizumab benefits in clear cell renal cell carcinoma, but some patients remain unresponsive.
First-line pembrolizumab “has consistent antitumor activity and safety” in patients with advanced urothelial carcinoma who are potentially ineligible for platinum‐based chemotherapy, researchers found ...
Data from expansion arms in Phase 1/1b clinical trial evaluating WTX-124 as monotherapy expected in first half of 2025 to guide regulatory ...
Data from expansion arms in Phase 1/1b clinical trial evaluating WTX-124 as monotherapy expected in first half of 2025 to guide regulatory engagement on potential registrational pathways - - Data from ...
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
Pembrolizumab started as “the poster child drug for melanoma”, according to Dr Burge, but is now used to treat lung, kidney, bladder, stomach, oesophagus, and bile duct cancers. The RBWH was ...
Lenvatinib/pembrolizumab and nivolumab/cabozantinib show improved survival and response rates in advanced renal cell carcinoma. Machine learning and surgical algorithms are advancing personalized ...
China NMPA approves Astellas Pharma’s Padcev in combination with Keytruda to treat advanced bladder cancer: Tokyo Thursday, January 9, 2025, 09:00 Hrs [IST] Astellas Pharma Inc.
The theory is solid, but creating such a bespoke vaccine quickly enough to be of use is a different matter. “Not many years ...
When Carter was diagnosed with metastatic melanoma, he told the country he'd be trying a new cutting-edge cancer treatment - immunotherapy.